Moberg Pharma AB announced that it has reached an agreement with its partner Meda to regain rights to Emtrix® in certain EU markets where the nail product has not yet been launched, including UK and Poland.

Moberg Pharma and Meda have agreed to amend their existing license and distribution agreement so Moberg regains rights to the nail product in certain EU markets. This includes UK, Poland, the Chech Republic and the Baltic countries. The two companies maintain their partnership in the remaining thirteen markets where the product has been launched under the brand names Naloc® and Nalox® and reached a leading or top 3 position in the majority of those markets.

“I am very pleased that we jointly agreed to focus our partnership on the majority of markets where it has been successful. We are evaluating options to launch by ourselves or through other distributors in the now released markets to further leverage the potential of Emtrix® in Europe” said Peter Wolpert, CEO of Moberg Pharma AB.